Dr. Geert Vanden Bossche and Dr. James Lyons-Weiler are giving a stunning set of lectures on COVID, yet focused on the pandemic & the evolutionary dance between the virus & the host/population immune

response & how both feed back on each other & drive adaptations to pressure they place on each other; we have readings to do & this passage is important I wish to share on MUCOSAL immunity & vaccine

‘Crucially, vaccines that are injected into the muscle—i.e., the interior of the body—will only induce IgG and circulating IgA, but not secretory IgA. The antibodies induced by such vaccines therefore cannot and will not effectively protect cells of the respiratory tract against infection by air-borne viruses [37, 38]. This realization is neither contentious nor particularly new. Even 30 years ago, McGhee et al. [38] concluded: It is surprising that despite our current level of understanding of the common mucosal immune system, almost all current vaccines are given to humans by the parenteral route [i.e. by injection].

Systemic immunization is essentially ineffective for induction of mucosal immune responses. Since the majority of infectious microorganisms are encountered through mucosal surface areas, it is logical to consider the induction of protective antibodies and T cell responses in mucosal tissues. The failure of intramuscular injection to induce secretory IgA was confirmed yet again in a recent study on Middle East Respiratory Syndrome (MERS) [39], which like COVID-19 is caused by a coronavirus of dubious origin. The experimental vaccine used in this study was genebased, like the major vaccines currently deployed against COVID-19.

With Pfizer’s COVID-19 vaccine, only feeble and short-lived induction of mucosal antibodies has been detected [40, 41].

With little or no secretory IgA, there is no reason to expect that vaccination will effectively inhibit replication of the virus within the mucous membranes.’